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Abstract: The presence of cataplexy in people with narcolepsy has a well-doc-
umented tight association with very low or non-detectable levels of the central 
nervous system neuropeptide, hypocretin (also termed orexin) while levels of hypo-
cretin are normal in people with narcolepsy without cataplexy. There is evidence to 
suggest that hypocretin may have an association with pain, migraines and head-
aches in people with narcolepsy. However, these studies have not compared find-
ings across narcolepsy with and without cataplexy. Currently, there are no studies 
published to determine whether pain, migraines and headaches are just common 
symptoms experienced by all people with narcolepsy or whether the presence of 
the cataplexy symptom (and thus assumed low levels of hypocretin) exacerbates 
these symptoms. Also, it is unclear whether general health and wellbeing (includ-
ing psychological wellbeing) is similarly affected by hypocretin levels, or may be 
confounded by different levels of other health symptoms, such as pain. This review 
poses a number of research questions that need to be explored about whether the 
presence or absence of cataplexy is differentially associated with different types, 
severity and location of chronic pain; frequency, location and types of migraines 
and headaches; and general health and wellbeing among people with narcolepsy. A 
greater understanding of the role of hypocretin in these health complaints could aid 
in the development of more appropriate treatments for pain, migraines and head-
aches amongst people with and without narcolepsy.
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1. Introduction
Narcolepsy is a disabling sleep disorder with an estimated mean prevalence of approximately 30 per 
100,000 people (Abde-Khalek, 2001; Cave, 1931; Daniels, 1934; Martikainen, Hasan, Urponen, Vuori, 
& Partinen, 1992; Ozdemir et al., 2005; Partinen & Hublin, 2005; Schmitt, Gugger, Augustiny, Bassetti, 
& Radanov, 2000; Schwegler et al., 2006; Szklo-Coxe, Young, & Mignot, 2003; The Gallup Organization, 
1997; Young et al., 1993). American studies have estimated a higher prevalence of 56 per 100,000 
(Silber, Krahn, Olson, & Pankratz, 2002). However, other studies have estimated a much lower preva-
lence rate of 15 per 100,000 people (Shin et al., 2008). These prevalence rates reflect both narco-
lepsy with and without cataplexy. Some researchers have attempted to identify the prevalence rate 
of narcolepsy with and without cataplexy separately. It is now estimated that the prevalence for 
narcolepsy with cataplexy is between 25 to 50 per 100,000 (Longstreth, Koepsell, Ton, Hendrickson, 
& van Belle, 2007; Nohynek et al., 2012; Partinen et al., 2012) and 20 to 34 per 100,000 for narcolepsy 
without cataplexy (Shin et al., 2008; Silber et al., 2002). Narcolepsy can develop at any age; however, 
research has identified bimodal peak ages of onset of 14.7 and 35 years, with an average age of 16 
(Silber, Krahn, & Slocumb, 2005). Often, if age of onset is in the teenage years there is a higher fre-
quency of cataplexy experienced by the diagnosed individual (Krishnamurthy, Nallamothu, & 
Singareddy, 2014). A family history of narcolepsy is uncommon; however, family members are at an 
increased risk of 1–2% for first degree relatives (Billiard et al., 1994; Mathew, 1994). Twin studies 
have also found a low concordance rate between monozygotic twins, with a 25% concordant for 
type 1 narcolepsy and 32% when looking at both type 1 and type 2 narcolepsy (Mignot, 1998). This 
sleep disorder has a negative effect on quality of life regardless of diagnostic or medication status 
(Daniels, King, Smith, & Shneerson, 2008; Ervik, Abdelnoor, Heier, Ramberg, & Strand, 2006; Goswami, 
2012; Kim et al., 2015; Rovere, Rossini, & Reimão, 2008). Quality of life is reduced due to the associ-
ated symptoms experienced with narcolepsy, the impairment it imposes on everyday living and the 
psychological symptoms that are expressed by an individual (Daniels et al., 2008; Kim et al., 2015). 
For a diagnosis of narcolepsy to be made, severe daytime sleepiness must be present. Also, one or 
more of the following symptoms may be present: sleep-onset or sleep-offset paralysis and/or hal-
lucinations and frequent movement and awakenings during sleep. A Multiple Sleep Latency Test 
(MSLT) is used to help make a diagnosis. The MSLT is a sleep disorder diagnostic tool that can distin-
guish between normal from abnormal daytime sleepiness (Dement, Mitler, Roth, Westbrook, & 
Keenan, 1986). A key feature of the MSLT and narcolepsy is a mean sleep latency of less than 8 min 
and two or more sleep-onset REM periods (Dement et al., 1986). To be diagnosed with narcolepsy 
with cataplexy, severe daytime sleepiness must be present and accompanied by episodes of a sud-
den loss of muscle tone, which are triggered by emotional arousal (Dauvilliers, Arnulf, & Mignot, 
2007). The sudden loss of muscle tone can be partial (e.g. affecting the face and/or neck) or com-
plete, resulting in a full body collapse. When a cataplexy attack occurs it usually lasts between 1 and 
2 min and the individual remains conscious. Approximately two thirds of people with narcolepsy 
suffer from cataplexy (Thannickal, Nienhuis, & Siegel, 2009). With the publication of the International 
Classification of Sleep Disorders – second edition in 2005, a formal distinction between narcolepsy 
with and without cataplexy was made. In 2014, The American Academy of Sleep Medicine (2014) 
determined that narcolepsy would be diagnosed as either narcolepsy type 1 (narcolepsy with 
 cataplexy) or narcolepsy type 2 (narcolepsy without cataplexy); therefore, for the remainder of this 
paper, narcolepsy with cataplexy will be referred to as narcolepsy type 1 and narcolepsy without 
cataplexy as narcolepsy type 2.
This review paper will present a brief history of cataplexy, its purported link to the neuropeptide 
hypocretin, and discuss key theories about how hypocretin may be involved in the symptoms of 
cataplexy and sleepiness. It will then discuss current research examining the differences between 
type 1 and type 2 narcolepsy (and thus presumed different hypocretin levels), with a focus on pain, 
migraines/headaches and general health and wellbeing in narcolepsy. Specific research questions 
that need to be answered will be posed. Answers to these questions are important as they will lead 
to a greater understanding of the role of hypocretin, the aetiology of selected health issues in people 
with narcolepsy and potentially aid in the development of more appropriate treatments for pain, 
migraines and headaches.
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2. The discovery of hypocretin’s role in narcolepsy
People with type 1 narcolepsy have been found mostly to have low or non-detectable levels of hypo-
cretin, whereas people with type 2 narcolepsy typically have normal levels (Dauvilliers et al., 2003; 
Heier et al., 2007; Kanbayashi et al., 2002; Krahn, Pankratz, Oliver, Boeve, & Silber, 2002; Savvidou 
et al., 2013). However, other studies have found that 10–30% of people with type 2 narcolepsy have 
low levels of hypocretin (Andlauer et al., 2012; Baumann et al., 2014). The neuropeptide hypocretin, 
which is also referred to as orexin, is involved in sleep and wakefulness. This neuropeptide is  produced 
in the lateral hypothalamus of the brain (Davis, Choi, & Benoit, 2011). Abnormally low hypocretin 
levels may be associated with other neurological conditions such as epilepsy (Rejdak, Papuć, Grieb, 
& Stelmasiak, 2009), Hashimoto’s encephalopathy (Castillo, Mignot, Woodruff, & Boeve, 2004) and 
head trauma (Ripley et al., 2001) (see Table 1). However, there is no evidence to suggest the  symptom 
of cataplexy exists among these neurological disorders.
The discovery of hypocretin was made in 1998 by two independent research groups, and this led 
to the neuropeptide having two names. One group (Sakurai et al., 1998) named it orexin, meaning 
“appetite” in Greek due to its involvement in food intake, and the other group (de Lecea et al., 1998) 
named it hypocretin due to the location in the brain where it is produced. For the purpose of this 
review paper, the neuropeptide will be referred to as hypocretin. Two years after hypocretin itself 
was identified, the link between low hypocretin in cerebrospinal fluid, loss of hypocretin cells and 
narcolepsy was observed (Crocker et al., 2005; Mignot et al., 2002; Peyron et al., 2000; Thannickal 
et al., 2000; Valko et al., 2013), and led to the proposal that narcolepsy is caused by a loss of hypo-
cretin cells when compared to healthy brains. It is unclear as to why there is a loss of hypocretin cells 
and wether people with a loss of hypocretin cells were born this way or if the loss occurred over time 
(Blouin et al., 2005; Nishino, Ripley, Overeem, Lammers, & Mignot, 2000; Peyron et al., 2000; 
Thannickal et al., 2000). However, it is understood that this loss leads to a reduction in the levels of 
hypocretin that is produced (Blouin et al., 2005; Nishino et al., 2000; Peyron et al., 2000; Thannickal 
et al., 2000). The loss of hypocretin cells refers to the cells that are located in the hypothalamus, 
which produce the neuropeptide hypocretin. A study that examined deceased brains of people with 
narcolepsy and people without any neurological disorders found that people with narcolepsy had 
85–95% less hypocretin cells compared to the brains without any neurological disorders (Thannickal 
et al., 2000). However, it was later revealed that lower hypocretin levels were mostly linked to cata-
plexy, which does not occur in approximately one-third of all people with narcolepsy (Thannickal 
et al., 2009). When brains of deceased people with type 2 narcolepsy were examined, it was found 
that there was only a 33% reduction in hypocretin cells compared to brains of deceased people 
without narcolepsy or any neurological disorders (Thannickal et al., 2009). Nevertheless, people with 
type 2 narcolepsy have been found to have a normal level of hypocretin in their cerebrospinal fluid 
(Mignot et al., 2002). Thannickal et al. (2009) theorised that people with narcolepsy either do or do 
not experience cataplexy depending on whether there has been a significant loss of hypocretin cells. 
That is, if an individual has lost a high percentage of hypocretin cells, this will cause them to experi-
ence cataplexy. However, the role of hypocretin in type 2 narcolepsy is not clearly understood.
3. Theories regarding hypocretin and narcolepsy symptoms
Some theories have been developed as to why low to non-detectable levels of hypocretin may be 
associated with cataplexy and sleepiness in people with narcolepsy. However, the actual physiologi-
cal mechanisms underpinning these two key aspects of narcolepsy, and a well-developed theoreti-
cal understanding, supported by evidence, of how hypocretin loss may increase sleepiness and/or 
lead to cataplexy has not yet been achieved.
3.1. Hypocretin and sleep state instability
Sleep state instability (also known as ‘behavioural state instability’) is a condition whereby the period 
of being awake is short and REM and non-REM sleep become mixed up with each other (Mochizuki, 
Crocker, McCoemack, Yanagisawa, & Sakurai, 2004). This condition causes fragmented sleep and 
wakefulness. This low threshold becomes apparent when observing and monitoring “orexin knock-
out” mice during sleep and wakefulness. These mice have been genetically modified not to produce 
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Table 1. Sleep and neurological disorders—association with hypocretin, pain and migraines
Hypocretin level Experience 
cataplexy
Experience 
pain
Experience 
migraines/
headaches
Reference 
Sleep disorders
Narcolepsy with 
cataplexy
Low hypocretin levels and 
loss of cells
Yes Yes Yes Castillo et al. (2004), Dauvilliers et al. 
(2007, 2011), Mignot et al. (2002) 
Narcolepsy without 
cataplexy
Loss of hypocretin cells No Further research 
is required
Further research 
is required
Weder-Cisneros et al. (2004) 
Idiopathic hypersom-
nia
Normal hypocretin levels and 
cell status unknown
No Further research 
is required
Further research 
is required
Mignot et al. (2002) 
Kleine Levin syndrome Low hypocretin levels during 
an episode
No No Further research 
is required
Li et al. (2013); Dahmen et al. (2003)
Neurodegenerative diseases
Alzheimer’s disease Low hypocretin levels and cell 
loss
No No Yes Ebrahim et al. (2003), Thannickal et al. 
(2009)
Dementia Reduced neocortical 
hypocretin-immunoreactivity
No Yes Further research 
is required
Donnelly and Leschziner (2016), Taiwo et 
al. (2007)
Parkinson’s disease Low hypocretin levels and cell 
loss
Yes Yes No evidence Fronczek et al. (2008), Ylikoski, Martikain-
en, Sarkanen, and Partinen (2015)
Huntington’s disease Loss of hypocretin cells No No No evidence Wolfe, Ross, Anderson, Russell, and 
Hebert (1995) 
Motor neurone 
disease
No research available No Yes No evidence McDermott and Shaw (2008) 
Demyelinating diseases of the central nervous system
Guillain-Barre 
syndrome
Low hypocretin level No Yes No evidence Fronczek et al. (2008)
Multiple sclerosis HLA DR15 positive Yes Yes No evidence Binder et al. (2016), Sandyk (1995)
Peripheral neuropa-
thies
No evidence No Yes No evidence Schestatsky (2007)
Autoimmune diseases
Inflammatory bowel 
disease
HLA DR2 positive No Yes Yes Orrell (2010), Peterson, Frank, Pace, and 
Gordon (2008), Rejdak et al. (2009)
Rheumatoid arthritis HLA DR2 positive No Yes Yes Farmakidis, Inan, Milstein, and Herskovitz 
(2015), Nishino (2003), Syvertsen et al. 
(2007)
Hashimoto disease Low hypocretin level No Yes No evidence Farmakidis et al. (2015), Rainero et al. 
(2011)
Miscellaneous neurological conditions
Acoustic schwan-
noma
Low hypocretin level No No Yes Ehde, Osborne, Hanley, and Kraft (2006), 
Schmidt, Williamson, and Ashley-Koch 
(2007)
Fibromyalgia Normal No Yes Yes Myung and Jin-Sang (2004), Nampia-
parampil (2008)
Epilepsy Low hypocretin level No No evidence Yes Baumann et al. (2007), Mainieri et al. 
(2015)
Migraines Genetic association with 
HCRTR1 gene
No No evidence Yes Theeler and Erickson (2009) 
Head trauma Loss of hypocretin neurons Yes Yes Yes Bruck and Broughton (2004), Choy (2012), 
Dimitrova et al. (2011), Strohmaier, 
Mueller-Eckhardt, and Meier-Ewert (1988)
Encephalitis Low hypocretin levels Yes No Yes Overeem, Reijntjes, Huyser, Jan Lammers, 
and Gert van Dijk (2004), Silva (2013)
Drop attacks Status unknown Yes No No Egel, Lee, Bump, and Javois (2012) 
Page 5 of 14
Gauci et al., Cogent Medicine (2017), 4: 1312791
http://dx.doi.org/10.1080/2331205X.2017.1312791
hypocretin. When the orexin knockout mice were compared to mice that had not been genetically 
modified, the orexin knockout mice had much briefer periods of wakefulness and REM sleep and they 
transitioned between states much more often (Mochizuki et al., 2004). The same pattern was found 
among dogs with genetic mutations in genes that encode for hypocretin receptors (Nishino et al., 
2000). That is, during periods of wakefulness hypocretin would activate neurons in particular sec-
tions of the brain that are associated with being awake to help maintain a wakeful state, and in turn 
neurons are activated to help maintain a state of sleep. This theory suggests that hypocretin is what 
creates a boundary between states of sleep and wakefulness. As mentioned, people with type 2 
narcolepsy have been found to have normal levels of hypocretin (Thannickal et al., 2009). Therefore, 
for this theory to account for people with type 2 narcolepsy, there would have to be a deficiency with 
the amount of neurons that produce hypocretin and not the amount of hypocretin found in the cer-
ebral spinal fluid (Thannickal et al., 2009).
3.2. Theories regarding cataplexy
It has been theorised that a cataplexy attack is actually REM sleep occurring during wakefulness 
(Burgess & Scammell, 2012). Cataplexy mimics the physiological response of REM sleep in that during 
REM sleep all skeletal muscles become paralysed. The only muscles that do not become paralysed are 
those around the eyes or involved in eye movements and the respiratory system. This is known as 
sleep atonia. This is what appears to occur during a cataplexy attack (Burgess & Scammell, 2012). 
Research has found that during REM sleep the release of norepinephrine and serotonin is suppressed 
(Winokur & Demartinis, 2012). Norepinephrine and serotonin are neurochemicals involved in the 
sleep-wake process. During wakefulness these neurochemicals are released to block REM sleep from 
occurring. It is hypothesised that when there are low or non-detectable levels of hypocretin the re-
lease of norepinephrine and serotonin is reduced. With a reduction in norepinephrine and serotonin a 
cataplexy attack occurs which resembles REM sleep during wakefulness (Burgess & Scammell, 2012).
However, this theory has been criticized. It is well documented that emotions trigger a cataplexy 
attack (Krahn, Lymp, Moore, Slocumb, & Silber, 2005; Sturzenegger & Bassetti, 2004) but this theory 
does not account for emotions triggering cataplexy (Overeem, Lammers, & van Dijk, 2002). Moreover, 
emotions do not trigger REM sleep and therefore do not trigger sleep atonia (Overeem et al., 2002). 
Instead, the theory of tonic immobility is proposed (Overeem et al., 2002). Tonic immobility can be 
described as, when an animal is faced with danger, they experience severe motor inhibition but re-
main fully conscious (Ginsburg, 1975). It is believed that strong emotions, such as fear, can trigger 
this response (Ginsburg, 1975). This theory could explain cataplexy in humans (Overeem et al., 
2002), extending the explanation to other strong emotions beyond fear.
Not much is known as to why strong positive emotions, such as laughter, will often trigger a cata-
plexy attack. It has been theorised that the amygdala and prefrontal cortex play a role, as these 
particular areas of the brain become active both when an individual expresses positive emotions 
(Burgess, Oishi, Mochizuki, Peever, & Scammell, 2013; Oishi et al., 2013) and during cataplexy (Oishi 
et al., 2013). The rationale behind this theory is that when positive emotions activate the amygdala 
and prefrontal cortex in people with type 1 narcolepsy, abnormal activity occurs in these areas of the 
brain, triggering a cataplexy attack (Oishi et al., 2013). When individuals with type 1 narcolepsy are 
shown humorous pictures, areas of the brain that are involved with the hypocretin system are acti-
vated. It is believed that this system may be impaired in people with type 1 narcolepsy due to a 
hypocretin deficiency. This impairment causes humour to trigger a cataplexy attack (Schwartz et al., 
2008). Interestingly, negative and neutral emotions, such as anger and surprise, also trigger a cata-
plexy attack (Sturzenegger & Bassetti, 2004).
Given that research has found that the left side of the prefrontal cortex is activated when negative 
emotions, such as anger and aggression, are expressed (Harmon-Jones & Sigelman, 2001), this the-
ory can also account for negative emotions. How the role of the amygdala and prefrontal cortex in 
cataplexy may interact with the loss of hypocretin producing cells in the lateral hypothalamus has 
not yet been addressed in these theories (Oishi et al., 2013).
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Another theory is that narcolepsy is caused by an autoimmune disease (Partinen et al., 2014). This 
theory proposes that the immune system attacks the neurons that produce hypocretin. This was 
seen with the 2009 influenza A H1N1 pandemic and vaccination with Pandemrix (Jacob et al., 2015; 
Saariaho et al., 2015). There was an increase in the diagnosis of narcolepsy with individuals who 
received one of these vaccinations. It was believed that this vaccination triggered an immune re-
sponse in some individuals that were already susceptible to narcolepsy. A particular antibody called 
Anti-GM3 was identified as being associated with the HLA-DQB1*0602 narcolepsy gene. These anti-
bodies were seen more frequently in individuals who received one of the vaccinations then individu-
als who did not (Saariaho et al., 2015).
4. Current and further hypocretin research
The role of hypocretin is currently being studied more closely across a range of behaviours and it is 
now known also to play an important role in appetite and humour. Research has found that appetite 
and arousal are activated by hypocretin (Preti, 2002; Tsujino & Sakurai, 2013). It has been known for 
several decades that damage to the lateral hypothalamus produced aphagia and weight loss 
whereas damage to the ventromedial nucleus of the hypothalamus resulted in hyperphagia and 
obesity (Bernardis & Bellinger, 1996; Oomura, 1980). Hypocretin, produced in the lateral hypothala-
mus, was subsequently found to activate appetite regulation and triggers food seeking and feeding 
behaviour (Sakurai, 2006). Also, research has found that the hypocretin system modulates human 
emotions; in particular, humour (Schwartz et al., 2008).
A number of findings (discussed below) suggest links between hypocretin activity and pain, head-
aches and migraines in people without narcolepsy. Furthermore, research has found that chronic 
pain (Dauvilliers et al., 2011), migraines (Dahmen et al., 2003), headaches (Miyamoto, Suzuki, 
Miyamoto, & Hirata, 2014) and reduced health and wellbeing (Dauvilliers et al., 2011) are signifi-
cantly more common in people with narcolepsy than people without a disorder of daytime sleepi-
ness. Reduced health and wellbeing refers to psychological symptoms such as depression, stress 
and anxiety experienced by an individual. It is unclear whether these symptoms are simply common 
among people with narcolepsy due to their sleep/wake problems or whether there is a specific link 
between these symptoms and low to non-detectable levels of hypocretin in those that have type 1 
narcolepsy. Since the initial discovery of hypocretin and studies elucidating the various roles it plays 
in human functioning, further research has been slow and many research questions remain unan-
swered, thus providing new opportunities for researchers in this area. Currently there are no pub-
lished studies that compare the expression of symptoms in relation to pain, migraines, headaches 
and general health and wellbeing amongst people with type 1 and 2 narcolepsy.
Throughout the following sections this review will present the available evidence in these areas 
and pose questions in relation to the hypothesised theories of hypocretin and its role in pain, mi-
graines, headaches and general health and wellbeing among people with narcolepsy. Understanding 
the effect of hypocretin in narcolepsy and its association with pain, migraines, headaches and gen-
eral health and wellbeing may provide knowledge to aid in the development of appropriate treat-
ment for these symptoms and thus improve quality of life.
4.1. Migraine and headaches
Migraines can be described as severe headaches that are accompanied by other symptoms. Other 
symptoms may include nausea, vomiting, sensitivity to light, sound and or smell. A relationship be-
tween sleep, migraines and headaches has been found (Bigal & Hargreaves, 2013). One explanation 
for this relationship concerns the unusual brain activity occurring in the hypothalamus, where hypo-
cretin is produced, before the onset of a migraine attack. This type of activity only occurred if a mi-
graine was going to follow (Alstadhaug, 2009; Cortelli & Pierangeli, 2007; Moulton, Becerra, Johnson, 
Burstein, & Borsook, 2014). This was found using positron emission tomography (Alstadhaug, 2009) 
and functional magnetic resonance imaging (Moulton et al., 2014) of people who were about to ex-
perience a migraine, and it continued throughout the migraine attack. Other relevant research has 
found that migraines and headaches are related to sleep. It is believed that migraines might cause 
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circadian rhythm disturbances (Solomon, Lipton, & Newman, 1992). It has been found that people 
who experience migraines show a circadian variation in migraine onset between 6am and 8am and 
with a decrease between 8 pm and 4 am (Solomon et al., 1992). This observation has also been 
found in people experiencing a myocardial infarction, platelet aggreability and when plasma cortisol 
and plasma catecholamines are present (Solomon et al., 1992). Also, changes to sleeping patterns 
and disturbed sleep can trigger a headache or migraine attack (Kelman & Rains, 2005). Kelman and 
Rains (2005) collected data using face to face interviews with the use of individually administered 
questionnaires about participants sleeping habits, migraine and headache diagnoses and other de-
mographic data. They found that participants that slept six hours, who were considered “short 
sleepers”, experienced more frequent severe headaches than participants that slept longer hours. 
Also, participants that experienced migraines, reported sleeping less hours and experienced more 
sleep disturbances than participants that did not experience migraines (Kelman & Rains, 2005).
A further study has found a mutation in the HCRT gene, which may make people more susceptible 
to migraines and cluster-headaches (Rainero et al., 2004, 2011). These findings were obtained by 
extracting genomic DNA from 109 cluster headache patients, 211 controls (Rainero et al., 2004) and 
384 migraine patients and 384 case-controls (Rainero et al., 2011). It could be hypothesised that the 
gene that produces hypocretin has a mutation in both people with narcolepsy with cataplexy and 
people who have migraines. However, another study that contained a larger sample size found no 
association with the HCRT gene (Anttila et al., 2010).
Research has produced conflicting results regarding the association between hypocretin and mi-
graines and/or headaches in people without narcolepsy but with low hypocretin levels. It has been 
found that headaches and migraines are a common symptom experienced amongst people with 
epilepsy (Syvertsen, Helde, Stovner, & Brodtkorb, 2007), Hashimoto encephalopathy (Huete, Sanchez-
del-Rio, & Franch, 2007) and head trauma (Theeler & Erickson, 2009); three conditions which have 
been found to have lower levels of hypocretin compared to people without a sleep disorder or neu-
rological condition (Castillo et al., 2004; Rejdak et al., 2009, 2001). However, particular care must be 
taken on this issue with regard to Hashimoto encephalopathy, which has been found to as research 
has found to mimic the symptoms of a migraine with aura (Huete et al., 2007). Thus it is hard to 
determine whether a person with Hashimoto is just experiencing the symptoms associated with the 
neurological condition or are experiencing a migraine attack. This opens up the possibility that 
 having lower levels of hypocretin could be associated with causes of migraines and headaches. 
However, a causal link must be viewed cautiously, with another study finding that the more anxious 
the chronic migraine patient was, the lower their hypocretin levels were (Peres et al., 2011).
Research examining migraines and headaches experienced by people with narcolepsy is limited 
and contradictory. One study found that it is common for people with narcolepsy to experience mi-
graines and headaches (Dahmen et al., 2003). Dahmen et al. (2003) administered various question-
naires that assessed migraines, headaches and narcolepsy symptoms to 100 people with narcolepsy 
and compared the findings amongst the participants within the study. Another study looked at the 
types of headaches and migraines experienced by people with narcolepsy and found that they did 
not experience more migraines than healthy participants, but did experience more tension-type 
headaches (The DMKG Study Group, 2003). This study consisted of 96 narcolepsy participants and 96 
age and sex matched control participants. Data collection included interviews, electroencephalog-
raphy, brain imaging, MSLTs and polysomnography. However, both these studies did not differenti-
ate between people with type 1 or 2 narcolepsy. Dauvilliers et al. (2011) did make this distinction and 
found that patients who suffered from type 1 narcolepsy did not experience more headaches than 
non-clinical participants. Their study used face-to-face interviews and questionnaires from 67 peo-
ple with type 1 narcolepsy and 67 age and sex matched healthy controls. To date, no other studies 
have looked at the difference in type of migraines and headaches experienced by people with nar-
colepsy and whether the presence or absence of cataplexy (and therefore presumably hypocretin) 
may be implicated. Thus, it remains to be determined whether at least some of the headaches and 
migraines in narcolepsy may be due to a hypocretin deficiency or if it is just a common symptom 
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experienced amongst people with narcolepsy (Dahmen et al., 2003) and unrelated to hypocretin 
levels. Accordingly, the following questions are proposed:
Do people with type 1 narcolepsy experience more migraines and headaches than people 
with type 2 narcolepsy and healthy controls?
And do people with type 1 narcolepsy experience a different location and type of migraine 
and headache than people with type 2 narcolepsy and healthy controls?
4.2. Experiencing pain
Research has investigated the symptoms of pain experienced by people with type 1 narcolepsy 
(Dauvilliers et al., 2011; Ervik et al., 2006). One study collected information using a questionnaire 
from 77 patients with type 1 narcolepsy regarding their quality of life (Ervik et al., 2006). Another 
study used face-to-face interviews and questionnaires to collect information from 67 people with 
type 1 narcolepsy regarding the presence and frequency of pain, narcolepsy symptoms and their 
quality of life (Dauvilliers et al., 2011). These studies found that pain was more often experienced 
amongst this population when compared with a healthy sample of participants. It is speculated that 
hypocretin has analgesic properties (Bingham et al., 2001; Kajiyama et al., 2005) and that this is re-
lated to stress-induced analgesia (SIA), the key behavioural component of the ‘fight or flight’ re-
sponse. Previous research has suggested that hypocretin regulates SIA, because when hypocretin is 
low or non-detectable, SIA is not adequately regulated (Bingham et al., 2001; Xie et al., 2008). 
Therefore, as people with type 1 narcolepsy have low to non-detectable levels of hypocretin, they 
may be more susceptible to experiencing pain, through a lower pain threshold. Furthermore, the 
location of pain experienced among people with type 1 narcolepsy in one particular study appears 
to be consistently reported as in their limbs, such as lower arm or lower leg, whereas people without 
a disorder of daytime sleepiness reported pain in their back or neck (Dauvilliers et al., 2011). However, 
these studies did not compare their findings across type 1 and 2 narcolepsy. It is unclear, therefore, 
whether hypocretin has an effect on the type, severity, and location of pain experienced, or if this is 
just a common symptom that people with narcolepsy suffer from. That is, sleepiness may, in itself, 
decrease pain tolerance. However, other studies have found that ongoing sleep disturbances, which 
causes sleepiness in people, increases spontaneous pain (Smith, Edwards, McCann, & 
Haythornthwaite, 2007) and increased sensitivity to pain (Chhangani et al., 2009). Therefore, the 
following question is proposed:
Do people with type 1 narcolepsy experience different types, severity and location of pain 
than people with type 2 narcolepsy and healthy controls?
Another factor which may explain the symptoms of pain experienced is the presence of migraines 
and/or headaches. As mentioned above, people with narcolepsy have been reported to have higher 
rates of reporting migraines and headaches. A recent study found that people in general who experi-
ence frequent migraines and/or headaches are more likely to experience widespread pain (Stuginski-
Barbosa, Dach, Bigal, & Speciali, 2012). In relation to applying these findings to people with 
narcolepsy, it can be argued that because people with narcolepsy may experience headaches and 
migraines, they are more likely to experience widespread pain. However, this is just a speculative 
association as no research has looked at whether there is a link between headaches/migraines and 
widespread pain amongst people with narcolepsy.
4.3. General health and wellbeing
Additionally, the general health and wellbeing of people with narcolepsy has been found to be re-
duced. People with narcolepsy often display symptoms that are associated with depression 
(Chellappa & Araújo, 2006), anxiety (Fortuyn et al., 2010) and stress (Berridge, Espana, & Vittoz, 
2010; Bruck, 2001). However, it is unclear as to why these symptoms are expressed.
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Hypocretin may play a role in the symptoms associated with depression. Recent evidence has 
shown a link between hypocretin and the dopaminergic pathways (Borgland & Labouèbe, 2010). 
Dopamine is a neurotransmitter that plays several important roles within the brain and body, includ-
ing depression (Dailly, Chenu, Renard, & Bourin, 2004). It has been found that when there are low to 
non-detectable levels of hypocretin, the release of dopamine is decreased, leading to depressive 
symptoms.
When mice displayed symptoms that were associated with depression, their hypocretin levels in 
the hippocampal region were reduced (Arendt et al., 2013). This suggests that hypocretin levels may 
play an active role in the expression of depressive symptoms. On the other hand, other studies sug-
gest that depressive symptoms experienced by people with narcolepsy are independent of hypocre-
tin (Jara, Popp, Zulley, Hajak, & Geisler, 2011; Lindsley & Crawford, 1996). These studies found that 
people with type 1 and 2 narcolepsy, all experienced symptoms of depression. That is, the level of 
hypocretin did not make a difference to the level of symptoms experienced with depression. Another 
study produced results that were unclear as to whether low levels of hypocretin contributed to the 
depressive symptoms or if the depression was due to suffering from pain (Dauvilliers et al., 2011). 
When an individual is suffering from chronic pain, their general health and wellbeing, and conse-
quently their psychological wellbeing, are affected (Kim et al., 2015).
The pathology of anxiety and stress experienced by people with narcolepsy is unclear. Studies 
have concluded that people with narcolepsy suffered more from anxiety, panic attacks (Fortuyn 
et al., 2010) and stress (Broughton & Broughton, 1994). This was found when comparing people with 
narcolepsy to normative values (Broughton & Broughton, 1994) and to a healthy case-control age 
and sex matched comparison group (Fortuyn et al., 2010). Similar results concerning psychosocial 
wellbeing were found when comparing people with narcolepsy to other illness groups (Bruck, 2001). 
This study compared the ‘mean’ total psychosocial adjustment scores of 129 people with type 1 
narcolepsy against normative scores of three other illness groups (using the Psychosocial Adjustment 
to Illness Scale). Bruck (2001) found that people with narcolepsy had more problematic psychosocial 
adjustment than the cardiac, mixed cancer or diabetes groups. Unfortunately, there appears to be 
no published research that compares symptoms associated with depression, anxiety and stress be-
tween people with type 1 and 2 narcolepsy. In researching this issue it would be important to control 
for the possible confounding symptoms of pain and migraines/headaches, given the above present-
ed research (albeit not with consistent findings) suggesting that people with type 1 narcolepsy may 
differ in the degree to which they experience pain and migraines/headaches compared to people 
with type 2 narcolepsy. Therefore, two further research questions are proposed:
Is the relationship between levels of pain and symptoms of anxiety and depression stronger 
in people with type 1 narcolepsy compared with people with type 2 narcolepsy and healthy 
controls?
Is the relationship between symptoms of migraines/headaches and symptoms of anxiety 
and depression stronger in people with type 1 narcolepsy compared with people with type 2 
narcolepsy and healthy controls?
One study suggested that people who suffer from chronic migraines and who have a higher level of 
anxiety have significantly lower levels of hypocretin when compared to people who suffer from 
chronic migraines and who have lower levels of anxiety (Peres et al., 2011). This was the first study 
that investigated migraine sufferers’ hypocretin levels in association with anxiety. It is unclear 
whether anxiety lowers levels of hypocretin or lower levels of hypocretin contribute to anxiety. It is 
also unclear whether experiencing migraines and headaches has an effect on symptoms associated 
with anxiety and depression. Thus a possible relationship between anxiety levels and the presence 
or absence of cataplexy could usefully be explored, where all groups being compared could experi-
ence migraine and/or headache symptoms.
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5. Summary and conclusion
Approximately two thirds of people with narcolepsy suffer from cataplexy (Thannickal et al., 2009). 
The presence of cataplexy in people with narcolepsy has a well-documented tight association with 
very low or non-detectable levels of the central nervous system neuropeptide, hypocretin (Heier et 
al., 2007; Savvidou et al., 2013), whereas further studies have shown that levels of hypocretin are 
normal in people without cataplexy (Silber et al., 2002). There is evidence to suggest that hypocretin 
has an effect on pain (Dauvilliers et al., 2011), migraines (Dahmen et al., 2003) and headaches (The 
DMKG Study Group, 2003). However, these studies have not compared these findings with a group of 
participants with Type 1 and 2 narcolepsy. Currently, there are no studies published to determine 
whether pain, migraines and headaches are just common symptoms experienced by all people with 
narcolepsy or whether the presence of the cataplexy symptom (and thus assumed low levels of 
hypocretin) exacerbates these symptoms. Also, it is unclear whether general health and wellbeing 
are similarly affected (Dauvilliers et al., 2011). Future research could move in the direction of inves-
tigating whether the presence or absence of cataplexy is differentially associated with different 
types, severity and location of chronic pain; frequency, location and types of migraines and head-
aches, and general health and wellbeing (including psychological wellbeing) among people with 
type 1 and 2 narcolepsy. Increased understanding the role of hypocretin in narcolepsy could provide 
knowledge to aid in the development of better treatments for pain, migraines and headaches among 
people with narcolepsy and possibly also for people without narcolepsy. Ultimately, this could help 
improve the quality of life for people with and without narcolepsy.
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